> Details

Speer, Claudius; Morath, Christian; Töllner, Maximilian; Buylaert, Mirabel; Göth, Daniel; Nusshag, Christian; Kälble, Florian; Schaier, Matthias; Grenz, Julia; Kreysing, Martin; Reichel, Paula; Hidmark, Asa; Ponath, Gerald; Schnitzler, Paul; Zeier, Martin; Süsal, Caner; Klein, Katrin; Benning, Louise

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
  • Contributor: Speer, Claudius; Morath, Christian; Töllner, Maximilian; Buylaert, Mirabel; Göth, Daniel; Nusshag, Christian; Kälble, Florian; Schaier, Matthias; Grenz, Julia; Kreysing, Martin; Reichel, Paula; Hidmark, Asa; Ponath, Gerald; Schnitzler, Paul; Zeier, Martin; Süsal, Caner; Klein, Katrin; Benning, Louise
  • imprint: Frontiers Media SA, 2021
  • Published in: Frontiers in Medicine
  • Language: Not determined
  • DOI: 10.3389/fmed.2021.721286
  • ISSN: 2296-858X
  • Origination:
  • Footnote:
  • Description: <jats:p>Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); <jats:italic>P</jats:italic> = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both <jats:italic>P</jats:italic> &amp;lt; 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both <jats:italic>P</jats:italic> &amp;lt; 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.</jats:p>
  • Access State: Open Access